Effectiveness of Delayed-Release Dimethyl Fumarate on Patient-Reported Outcomes and Clinical Measures in Patients With Relapsing–remitting Multiple Sclerosis in a Real-World Clinical Setting: PROTEC

Multiple Sclerosis Journal - Experimental, Translational and Clinical
doi 10.1177/2055217319887191
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

A Retrospective Analysis of Real-World Discontinuation Rates With Delayed-Release Dimethyl Fumarate in Patients With Relapsing–Remitting Multiple Sclerosis

Neurology and Therapy
Neurology
2019English

Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting

Journal of Neurology & Neurophysiology
2015English

Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients With Relapsing Forms of Multiple Sclerosis (MANAGE)

International Journal of MS Care
NeurologySpecialized NursingAdvanced
2016English

The Real-World Effectiveness and Safety of Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients: An Observational Study

PLoS ONE
Multidisciplinary
2017English

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients With Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies

Neurology and Therapy
Neurology
2016English

Real-Life Effectiveness of Natalizumab in Relapsing-Remitting Multiple Sclerosis (Rrms): A Registry Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Nonfatal PML in a Patient With Multiple Sclerosis Treated With Dimethyl Fumarate

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2016English

Budget Impact Analysis of Delayed-Release Dimethylfumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Pnd117 - Physician Reported Adherence in Ms Patients Treated With Injectable Platform Therapies Versus Delayed-Release Dimethyl Fumarate: Findings From a Real-World Cross-Sectional Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy